{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:58:01Z","timestamp":1789178281504,"version":"build-2803163510"},"reference-count":27,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2018,9,18]]},"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor therapy is a modern breakthrough in medical oncology, but it can precipitate inflammatory and autoimmune adverse effects. Among the most serious of these toxicities is haemophagocytic lymphohistiocytosis (HLH), a life-threatening disorder of unbridled immune activation that results in injury to multiple organ systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Description of a case of pembrolizumab-associated HLH in a patient with a proposed underlying genetic risk factor for its occurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>\n                      We describe a patient with aggressive metastatic breast cancer who developed HLH while undergoing experimental treatment with pembrolizumab, resulting in critical illness and multiorgan system failure. Pembrolizumab discontinuation and high-dose corticosteroids were effective in managing HLH. Subsequent next-generation sequencing of 15 genes associated with HLH revealed a germline polymorphism in perforin-1 (\n                      <jats:italic>PRF1<\/jats:italic>\n                      ),\n                      <jats:italic>PRFA91V<\/jats:italic>\n                      , that may have predisposed the patient to develop HLH. The patient has had no evidence of malignancy for 2 years following recovery despite receiving no further cancer-directed treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      HLH is a rare but serious complication of immune checkpoint blockade. Patients with underlying hypomorphic alleles in\n                      <jats:italic>PRF1<\/jats:italic>\n                      may be predisposed to develop this toxicity. Further studies are necessary to confirm a possible link between perforin gene mutations and immune checkpoint blockade-associated HLH.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jmedgenet-2018-105485","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T12:16:21Z","timestamp":1538655381000},"page":"39-42","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the\n                    <i>PRF1A91V<\/i>\n                    gene polymorphism"],"prefix":"10.1136","volume":"56","clinical-trial-number":[{"clinical-trial-number":"nct02513472","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02513472","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1383","authenticated-orcid":false,"given":"Hanny","family":"Al-Samkari","sequence":"first","affiliation":[{"name":"Center for Hematology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D","family":"Snyder","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M","family":"Tolaney","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A","family":"Freedman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie-Aurore","family":"Losman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,10,4]]},"reference":[{"key":"2026041402301142000_56.1.39.1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1051"},{"key":"2026041402301142000_56.1.39.2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-041610-134208"},{"key":"2026041402301142000_56.1.39.3","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2026041402301142000_56.1.39.4","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039"},{"key":"2026041402301142000_56.1.39.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-356261"},{"key":"2026041402301142000_56.1.39.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04302.x"},{"key":"2026041402301142000_56.1.39.7","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/pbc.25646","article-title":"Spectrum of Atypical Clinical Presentations in Patients with Biallelic PRF1 Missense Mutations","volume":"62","author":"Tesi","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2026041402301142000_56.1.39.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-278127"},{"key":"2026041402301142000_56.1.39.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-313X.2006.00582.x"},{"key":"2026041402301142000_56.1.39.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-313X.2007.00679.x"},{"key":"2026041402301142000_56.1.39.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-370148"},{"key":"2026041402301142000_56.1.39.12","doi-asserted-by":"publisher","DOI":"10.1086\/318796"},{"key":"2026041402301142000_56.1.39.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3713"},{"key":"2026041402301142000_56.1.39.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4935"},{"key":"2026041402301142000_56.1.39.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61048-X"},{"key":"2026041402301142000_56.1.39.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"2026041402301142000_56.1.39.17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026041402301142000_56.1.39.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788349"},{"key":"2026041402301142000_56.1.39.19","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/cncr.30826","article-title":"A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults","volume":"123","author":"Daver","year":"2017","journal-title":"Cancer"},{"key":"2026041402301142000_56.1.39.20","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-150"},{"key":"2026041402301142000_56.1.39.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"2026041402301142000_56.1.39.22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","article-title":"Hemophagocytic Lymphohistiocytosis","volume":"13","author":"Al-Samkari","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"2026041402301142000_56.1.39.23","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood.V126.23.LBA-3.LBA-3","article-title":"NI-0501-04 Study Group, De Min, C. A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFN\u03b3) Monoclonal Antibody (mAb), NI-0501: first results from a pilot phase 2 study in children with primary HLH","volume":"126","author":"Jordan","year":"2015","journal-title":"Blood"},{"key":"2026041402301142000_56.1.39.24","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/annonc\/mdx113","article-title":"Pembrolizumab associated hemophagocytic lymphohistiocytosis","volume":"28","author":"Shah","year":"2017","journal-title":"Ann Oncol"},{"key":"2026041402301142000_56.1.39.25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2018.01.063","article-title":"Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab","volume":"93","author":"Satzger","year":"2018","journal-title":"Eur J Cancer"},{"key":"2026041402301142000_56.1.39.26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/annonc\/mdw537","article-title":"Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression","volume":"28","author":"Takeshita","year":"2017","journal-title":"Ann Oncol"},{"key":"2026041402301142000_56.1.39.27","doi-asserted-by":"crossref","first-page":"1602-1603","DOI":"10.1093\/annonc\/mdy175","article-title":"Hemophagocytic lymphohistiocytosis associated with dabrafenib and trametinib combination therapy following pembrolizumab administration for advanced melanoma","volume":"29","author":"Sasaki","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmedgenet-2018-105485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T09:31:39Z","timestamp":1776159099000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmedgenet-2018-105485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,4]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12,13]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1136\/jmedgenet-2018-105485"],"URL":"https:\/\/doi.org\/10.1136\/jmedgenet-2018-105485","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,4]]}}}